Controversies in treatment deintensification of human papillomavirus- associated oropharyngeal carcinomas: Should we, how should we, and for whom?

Journal of Clinical Oncology

Volumn 31, Issue 5, 2013, Pages 520-522

  Quon, Harry ^a   Forastiere, Arlene A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; PACLITAXEL;

CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; DISTANT METASTASIS; DYSPHAGIA; EDITORIAL; ENTERIC FEEDING; GASTROSTOMY; HUMAN; HUMAN PAPILLOMAVIRUS ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RECURRENCE FREE SURVIVAL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT DEINTENSIFICATION; TREATMENT PLANNING; WART VIRUS;

ALPHAPAPILLOMAVIRUS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS;

EID: 84875478416     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.7746     Document Type: Editorial

References (22)

1. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-720, 2000 (Pubitemid 30365531)
2. Lowy DR, Munger K: Prognostic implications of HPV in oropharyngeal cancer. N Engl J Med 363:82-84, 2010
3. Gillison ML, D'Souza G, Westra W, et al: Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16- negative head and neck cancers. J Natl Cancer Inst 100:407-420, 2008 (Pubitemid 351480511)
4. Fakhry C, Westra WH, Li S, et al: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261-269, 2008 (Pubitemid 351480538)
5. Rischin D, Young RJ, Fisher R, et al: Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 28:4142-4148, 2010
6. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
7. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, et al: Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26:3770-3776, 2008
8. de Arruda FF, Puri DR, Zhung J, et al: Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: The Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 64:363-373, 2006 (Pubitemid 43083420)
9. Rusthoven KE, Raben D, Ballonoff A, et al: Effect of radiation techniques in treatment of oropharynx cancer. Laryngoscope 118:635-639, 2008 (Pubitemid 351496757)
10. Quon H, Richmon JD: Treatment deintensification strategies for HPVassociated head and neck carcinomas. Otolaryngol Clin North Am 45:845-861, 2012
11. Sanguineti G, Sormani MP, Marur S, et al: Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys 83:235-242, 2012
12. O'Sullivan B, Huang SH, Siu LL, et al: Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 31:543-550, 2013
13. Gillison ML, Zhang Q, Jordan R, et al: Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 30:2102-2111, 2012
14. Maxwell JH, Kumar B, Feng FY, et al: Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 16:1226-1235, 2010
15. Farshadpour F, Kranenborg H, Calkoen EV, et al: Survival analysis of head and neck squamous cell carcinoma: Influence of smoking and drinking. Head Neck 33:817-823, 2011
16. Cohen EEW, Karrison T, Kocherginsky M, et al: DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 30:356s, 2012 (suppl; abstr 5500)
17. Haddad RI, Rabinowits G, Tishler RB, et al: The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). J Clin Oncol 30:356s, 2012 (suppl; abstr 5501)
18. Haughey BH, Hinni ML, Salassa JR, et al: Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: A United States multicenter study. Head Neck 33:1683-1694, 2011
19. Weinstein GS, O'Malley BW Jr, Cohen MA, et al: Transoral robotic surgery for advanced oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 136:1079-1085, 2010
20. O'Malley BW Jr, Quon H, Lin A, et al: Transoral robotic surgery for selected T3 or T4 oropharyngeal squamous cell carcinomas. Presented at the 8th International Conference on Head and Neck Cancer, Toronto, CA, July 22, 2012
21. Lewis JS Jr, Carpenter DH, Thorstad WL, et al: Extracapsular extension is a poor predictor of disease recurrence in surgically treated oropharyngeal squamous cell carcinoma. Mod Pathol 24:1413-1420, 2011
22. Gokhale AS, McLaughlin BT, Flickinger JC, et al: Clinical and dosimetric factors associated with a prolonged feeding tube requirement in patients treated with chemoradiotherapy (CRT) for head and neck cancers. Ann Oncol 21:145- 151, 2010